Vertex
Nobel winner Charpentier’s CRISPR Therapeutics gets $900m in reworked Vertex deal
Richard Staines
CRISPR, CRISPR Therapeutics, Editas, gene editing, Vertex
0 Comment
News/ News/ News/ R&D/ Sales and Marketing
After Celgene deal, BMS shoots up pharma market cap rankings
Phil Taylor
AbbVie, Amgen, AstraZeneca, Bayer, Biogen, Bristol-Myers Squibb, CSL, Daiichi Sankyo, Eli Lilly, Gilead Sciences, GlaxoSmithKline, GlobalData, Johnson & Johnson, M&A, Merck & Co, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Takeda, Vertex
0 Comment
Digital/ News/ News/ Top stories
COVID-19 could cause surge in virtual trials, says Vertex expert
Richard Staines
coronavirus, COVID-19, digital, R&D, Vertex, virtual trials
0 Comment
Market Access/ News/ News/ Top stories
Shares in Vertex jump on overnight success of CF triple therapy
Richard Staines
COVID-19, cystic fibrosis, market access, pricing, Trikafta, Vertex
0 Comment
Market Access/ Views & Analysis/ Views and analysis
The 4 biggest pharma market access stories of 2019
George Underwood
biosimilars, cystic fibrosis, fda, HTA, NICE, pricing, Vertex
0 Comment
Market Access/ News/ News/ Top stories
After four-year wait, patients in England finally get Vertex’s cystic fibrosis drugs
Richard Staines
cystic fibrosis, market access, Vertex
0 Comment
News/ News/ R&D/ Top stories
Vertex looks beyond cystic fibrosis with $950m Semma buy
Phil Taylor
M&A, metabolic diseases, stem cell therapy, type 1 diabetes, Vertex
0 Comment
Scotland’s cost regulator rejects Vertex cystic fibrosis drugs
Richard Staines
cost-effectiveness, cystic fibrosis, market access, Rare diseases, Vertex
0 Comment